Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

By sjmartinez • January 13, 2025

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575-3. Epub ahead of print. PMID: 39798578.

Tags: Hematology/Oncology, Publications

Medical Societies in the United States: History, Purpose, Challenge, and Future Directions

Schiller G, Leer LR. Medical Societies in the United States: History, Purpose, Challenge, and Future Directions. Cureus. 2026 Jul 10;18(7):e112407. doi: 10.7759/cureus.112407. PMID: 42572655; PMCID:[...]

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, Bardia A, Sedrak MS. Patient-reported outcomes in clinical trials leading to breast cancer[...]

Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways

Hsu JH, Shi Y, Frost P, Yan H, Hoang B, Sharma S, Gera J, Lichtenstein A. Editorial Expression of Concern: Interleukin-6 activates phosphoinositol-3' kinase in[...]